Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) will post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.18) per share for the quarter.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The firm had revenue of $50.47 million for the quarter. On average, analysts expect Vanda Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Vanda Pharmaceuticals Price Performance
VNDA stock traded up $0.12 during trading on Thursday, reaching $4.68. 355,123 shares of the stock traded hands, compared to its average volume of 1,322,552. The business's 50 day moving average price is $4.86 and its 200-day moving average price is $5.23. The firm has a market capitalization of $272.80 million, a PE ratio of -24.84 and a beta of 0.77. Vanda Pharmaceuticals has a 52-week low of $3.30 and a 52-week high of $6.75.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on VNDA. Cantor Fitzgerald boosted their price objective on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, August 1st. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research note on Thursday, October 24th. They issued a "hold" rating on the stock. Finally, HC Wainwright assumed coverage on Vanda Pharmaceuticals in a research note on Thursday. They issued a "buy" rating and a $18.00 price target on the stock.
Check Out Our Latest Stock Report on VNDA
About Vanda Pharmaceuticals
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
See Also
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
